

Molecules 2012, 17, 179-190; doi:10.3390/molecules17010179

OPEN ACCESS

molecules

ISSN 1420-3049

www.mdpi.com/journal/molecules

Article

Synthesis of 1,4-Disubstituted Mono and Bis-triazolocarboacyclonucleoside Analogues of 9-(4-Hydroxybutyl)guanine by Cu(I)-Catalyzed Click Azide-Alkyne Cycloaddition

Jamal Krim ^{1,2}, Moha Taourirte ¹ and Joachim W. Engels ^{2,*}

¹ Laboratoire de Chimie Bioorganique et Macromoléculaire, Faculté des Sciences et Techniques - Guéliz, 40000, Marrakech, Maroc

² Institut für Organische Chemie und Chemische Biologie, J.W. Goethe Universität, Max-von-Laue Str. 7, 60438 Frankfurt am Main, Germany

* Author to whom correspondence should be addressed;

E-Mail: joachim.engels@chemie.uni-frankfurt.de; Tel.: +49-69-7982-9150; Fax +49-69-7982-9148.

Received: 16 November 2011; in revised form: 9 December 2011 / Accepted: 19 December 2011 /

Published: 27 December 2011

Abstract: A series of novel mono-1,2,3-triazole and bis-1,2,3-triazole acyclonucleoside analogues of 9-(4-hydroxybutyl)guanine was prepared *via* copper(I)-catalyzed 1,3-dipolar cycloaddition of *N*-9 propargylpurine, *N*-1-propargylpyrimidines/as-triazine with the azido-pseudo-sugar 4-azidobutylacetate under solvent-free microwave conditions, followed by treatment with K₂CO₃/MeOH, or NH₃/MeOH. All compounds studied in this work were screened for their antiviral activities [against human rhinovirus (HRV) and hepatitis C virus (HCV)] and antibacterial activities against a series of Gram positive and negative bacteria.


Keywords: 1,3-dipolar cycloaddition; 1,2,3 triazole; 1,2,3-bis-triazoles; click azide-alkyne; microwave-assisted synthesis; antibacterial activities

1. Introduction

For several years, there has been an intensive search for drugs effective in chemotherapy of viral diseases like AIDS, herpes simplex, Hepatitis C and cytomegaloviruses [1-5]. Most of these drugs are analogues of naturally occurring nucleosides [6]. A series of nucleoside analogues were synthesised in which the cyclic carbohydrate moiety was replaced by an acyclic side chain [7-12]. The biological

activities of acyclonucleosides, after the discovery of acyclovir [9-((2-hydroxyethoxy) methyl)guanine ACV (Zovirax)] (**1**, Figure 1), have led to the synthesis of a diversity of structures. Many variations were tested in order to enhance biological activity and selectivity, or to lower toxicity [13-18]. Among them HBG [9-(4-hydroxybutyl)guanine] (**2**, Figure 1) presented good activity against HSV-1 and HSV-2.

Figure 1. Examples of drugs effective in chemotherapy.



On the other hand, for antiviral agents, triazoloneucleosides and acyclonucleosides have attracted much attention. Ribavirin (**3**, Figure 1), whose nucleobase consists of an unnatural triazole moiety, was the first synthetic nucleoside to show a broad spectrum of antiviral activities against many RNA and DNA viruses [19]. Furthermore, nucleosides with unnatural triazole nucleobases are generally resistant to nucleos(t)ide metabolizing enzymes, and this may lead to better *in vivo* stability and efficiency. Because of their broad application as pharmaceuticals like antibacterial or antiviral agents, a great number of 1,2,3-triazole derivatives have been reported as potent antiviral, antimicrobial or antiproliferative agents [20]. Also the synthesis and biological evaluation of carbonucleosides (substances in which the anomeric oxygen of the furanose ring is replaced by a methylene group), having a 1,2,3-triazole ring as a nucleobase (e.g., **4**, Figure 1) have been reported. Until now, very few efforts were made on appending aromatic systems to triazole nucleosides. We expect that these extended aromatic systems may offer advantageous binding properties to the corresponding biological targets via larger aromatic systems.

2. Results and Discussion

Different synthetic methods have been developed for the construction of triazole frameworks. These compounds are typically prepared by thermal cycloaddition of azides and alkynes [21,22]. Two problems are, however, encountered in this transformation: (1) reactivity of the substrates, either alkynes or azides require activation by an electron withdrawing group, otherwise, the reaction must be carried out at higher temperatures; (2) the regioselectivity of the products, as for unsymmetrical alkynes, a mixture of regioisomers is obtained in most cases. Since Sharpless reported copper(I)


catalysis for regioselective cycloaddition of terminal alkynes and azides to yield exclusively 1,4-disubstituted-1,2,3-triazoles, many groups have reported their results employing different kinds of Cu(I) salts as catalyst [23-35]. In addition, microwave irradiation has become a powerful synthetic tool for rapid synthesis of a variety of biologically active compounds. Its use is to enhance the rates of classical organic reactions.

In the light of these findings and in continuation of our previous investigation [34], we considered the synthesis of new 1,2,3-triazole and bis-1,2,3-triazole acyclonucleosides. They carry either a purine, pyrimidine or as-triazine moiety as nucleobase appended to 1,2,3-triazole. They can be regarded as analogues of 9-(4-hydroxybutyl)guanine (HBG). We went further to combine nucleobase and triazole rings with an acyclic side-chain developed bistriazolyl acyclonucleosides, and determined their *in vitro* antiviral and antibacterial activities.

2.1. Chemistry


The starting material 4-azidobutylacetate (**7**) was prepared according to the literature [34,36] from 4-bromobutylacetate (**6**) and sodium azide at 90–95 °C for 4 h (Scheme 1).

Scheme 1. Synthesis of the azidobutylacetate **7** from bromobutylacetate **6**.



The second step of the synthesis was the preparation of monopropargylated nucleobases. For this, uracil, thymine, 6-azauracil and adenine were used as starting materials that were treated with propargylbromide in the presence of K₂CO₃. All reactions were carried out in DMF, as it is an excellent solvent for dissolving nucleobases [34] (Scheme 2). The pyrimidine and as-triazine derivatives were exclusively alkylated at the *N*-1 position, (**9a–c**), and the purine in *N*-9 position, (**9d**) as confirmed by ¹H-NMR and ¹³C-NMR spectra.



















Scheme 2. Preparation of mono-triazolo-carboacyclonucleosides **10a–d**.



Reagents and conditions: (i) K₂CO₃, DMF, 24 h; (ii) (1) CuI, Et₃N, MW; (2) MeOH/ K₂CO₃ or NH₃/MeOH.

The terminal triple bonds of propargylated nucleobases were ligated to the azide residue of the pseudosugar using copper(I)-catalyzed 1,3-dipolar cycloaddition and Et_3N under microwave-assisted reaction without solvent [34] (Scheme 2) leading to the 1,4-disubstituted regioisomer in a quantitative yield unlike before [22] and a reaction time of one minute (Table 1). We intimately mixed the azide, acetylenic derivative and copper(I)-iodide prior to microwave irradiation. This fast and efficient method was in all tested cases superior in yield and handling to running the reaction in solution [34].

Table 1. Structures of the starting azides, alkynes and corresponding products.

Entry	Azide	Alkyne	Reaction time	Product ^a	Yields(% ^b)
10a			1 min		91
10b			1 min		92
10c			1 min		90
10d			1 min		89
12a			1 min		90
12b			1 min		92

The structure of all compounds was confirmed on the basis of ^1H -, ^{13}C -NMR spectra and mass spectra. Formation of 1,4-disubstituted triazoles was unequivocally established by the characteristic chemical shift values of the triazolyl proton (5-CH) at $\delta = 7.91\text{--}8.10$ ppm. The triazole ring formation can also be identified from the ^{13}C -spectra with the new signals of the olefinic C-atoms of the 1,2,3-triazole moiety at (δ (C5) = 122.94–123.39 ppm) and (δ (C4) = 141.48–145.44 ppm).

2.2. Biological Results

2.2.1. Antibacterial Activity

The antibacterial activity of all the synthesized compounds **10a–d** and **12a–c** were examined against different Gram-positive *Staphylococcus aureus* (ATCC 13709 *in vivo*, ATCC 25923, oxford and MRSA *in vivo*), *Enterococcus faecalis* (ATCC 29212 VanS), *Enterococcus faecium* (VanA), *Streptococcus pneumoniae* (VanA, ATCC49619, PenR and Blood effect), and Gram-negative *Haemophilus influenzae* (ATCC 31517 MMSA), *Escherichia coli* (ATCC 25922) *Pseudomonas aeruginosa* (ATCC 27853). We measured the minimum inhibitory concentration (MIC) values, which are defined as the lowest concentration of an antimicrobial that visibly inhibits the growth of the bacteria after an overnight incubation [37]. Ciprofloxacin and linezolid were used as standard drugs for comparison (Table 2). As shown in Table 2, no antibacterial activities against Gram-positive and Gram-negative bacteria were noted. All compounds showed antibacterial activity with a range of the MICs higher than 64 $\mu\text{g/mL}$.

Table 2. Minimum inhibitory concentration (MIC) in $\mu\text{g/mL}$ of medium.

Strains		Phenotype	Cipro	Lin	10a	10b	10c	10d	12a	12b	12c
1	Sa1	ATCC13709 <i>in vivo</i>	0.12	1	>64	>64	>64	>64	>64	>64	>64
2	Sa26	ATCC25923	0.25	1	>64	>64	>64	>64	>64	>64	>64
3	Sa26 + 10% Human serum	Serum effect	0.25	1	>64	>64	>64	>64	>64	>64	>64
4	Sa26 + 50% Human serum	Serum effect	0.5	2	>64	>64	>64	>64	>64	>64	>64
5	Sa4	Oxford	0.12	1	>64	>64	>64	>64	>64	>64	>64
6	Sa2	MRSA, <i>in vivo</i>	8	1	>64	>64	>64	>64	>64	>64	>64
7	<i>E. faecalis</i>	Ecalis1 ATCC29212 VanS	0,5	2	>64	>64	>64	>64	>64	>64	>64
8	<i>E. faecium</i>	Ecium1 VanA	16	0.5	>64	>64	>64	>64	>64	>64	>64
9	<i>S. pneumoniae</i>	Pn1 ATCC49619	1	1	>64	>64	>64	>64	>64	>64	>64
10		Pn9 PenR	0.5	0.5	>64	>64	>64	>64	>64	>64	>64
11		Pn9+2.5% blood Blood effect	0.5	0.25	>64	>64	>64	>64	>64	>64	>64
12	<i>H. influenzae</i>	Hi3 ATCC 31517 MMSA	≤ 0.03	16	>64	>64	>64	>64	>64	>64	>64
14	<i>E. coli</i>	Ec1 ATCC25922	≤ 0.03	>32	>64	>64	>64	>64	>64	>64	>64
16	<i>P. aeruginosa</i>	Pa1 ATCC 27853	0,25	>32	>64	>64	>64	>64	>64	>64	>64

Cipro: Ciprofloxacin; Lin: Linezolid.

2.2.2. Antiviral Activity and Cytotoxicity

Antiviral activities of the synthesized compounds were screened against two types of viruses in human epithelial (HeLa) cells for HRV and Human hepatocarcinoma (Huh) cells for HCV. For each compound, the 50% and 90% effective concentration (EC_{50} , EC_{90}) and the minimal toxic concentration (MTC) or the 50% cytotoxic concentration (CC_{50}) was obtained. None of the compounds exhibited specific antiviral activity, which means that they did not inhibit the replication (induction of viral cytopathogenicity) of any of the viruses tested.

3. Experimental

3.1. General

NMR spectra were recorded at 250 MHz and 300 MHz (1H , ^{13}C) Bruker in ($DMSO-d_6$, $CDCl_3$) using TMS as an internal reference. All chemical shifts (δ) are expressed in parts per million (s, singlet; d, doublet; t, triplet; and m, multiplet) and coupling constants (J) are given in Hertz; T (1,2,3-triazole) and B (heterocyclic base). Mass spectra were obtained by using MALDI-TOF and (FAB^+). Reactions were performed in a domestic microwave oven Model AVM510/WP/WH. DMF was distilled prior to use and stored over molecular sieves 4A. Precoated Merck Silica Gel 60F-254 plates were used for thin layer chromatography (TLC) and the spots were detected under UV light (254 nm). Column chromatography (CLC) was performed using silica gel (0.063–0.2 mm) Fluka. All reagents used were purchased from Aldrich. MICs were determined based on CLSI methodology [37] by a 2-fold broth dilution technique in Mueller Hinton (MH, pH 7.4 Biorad). For *S.pneumoniae* the medium was Brain Heart Infusion broth + 4% red blood cell extract. For *H. influenzae* the medium was HTM (Haemophilus Test Medium consisting of MH + 5 g/L yeast extract + hemin 15 mg/L + NAD 20 mg/L). Overnight cultures were diluted to obtain the final inoculum of 10^5 cfu/well. Incubation was 37 °C overnight in ambient air. 4-Bromobutylacetate (**6**) and 4-azidobutylacetate (**7**) were prepared as described below.

4-Bromobutylacetate (**6**). To distilled acetyl bromide (100 mmol, 12.3 g) was added tetrahydrofuran (100 mmol, 7.2 g) dropwise while agitating and cooling with an ice bath. The reaction is fast and exothermic. After addition, the reaction is agitated further during 30 min at room temperature and afterwards the reaction mixture was distilled under reduced pressure. Boiling Point: 92–93 °C (12 mmHg) (96%), 1H -NMR ($CDCl_3$, δ): 1.6 (m, 4H, CH_2CH_2); 2.0 (s, 3H, CH_3COO); 3.48 (t, 2H, CH_2Br); 4.03 (t, 2H, OCH_2).

4-Azidobutylacetate (**7**). To a solution of 4-bromobutylacetate (**6**, 10 mmol, 2 g) in anhydrous DMF (60 mL) was added sodium azide (NaN_3 , 15 mmol, 0.9 g). The mixture was brought up to a temperature of 90–95 °C during 4 h. After cooling, the solution was extracted with ether (2×50 mL) then washed with brine, and dried ($MgSO_4$). After removal of the solvents under reduced pressure, the residual oil was purified on a silica gel column with hexane (91%). 1H -NMR ($CDCl_3$, δ): 1.64 (m, 4H, CH_2CH_2); 2.0 (s, 3H, CH_3COO); 3.3 (t, 2H, OCH_2); 4.1 (t, 2H, CH_2N_3).

3.2. General Procedure for the Synthesis of Monopropargyl Heterocyclic Bases

The mixture of heterocyclic base (thymine, uracil, 6-azauracil and adenine, 1 mmol), K₂CO₃ (0.5 mmol) and propargyl bromide (1 mmol) in anhydrous DMF (20 mL) was stirred at room temperature during 24 h. After removal of the solvent under reduced pressure the residue obtained was purified on a silica gel column eluted with CH₂Cl₂ and MeOH (99/1).

N-1-propargyl-6-azauracil (**9c**). Yield: 55%. ¹H-NMR (DMSO-d₆, δ): 3.91 (t, 1H, CH); 4.45 (d, 2H, CH₂N); 7.46 (s, 1H, H-5); 11.44 (s, 1H, NH). ¹³C-NMR (DMSO-d₆, δ): 28.37; 73.11; 77.53; 134.61; 148.36; 155.41. FAB-MS, *m/z* calcd for C₆H₅N₃O₂ (M+H)⁺ 152.04 found, 152.

3.3. General Procedure for the Synthesis of the *N*-1, *N*-3-Bis-propargylpyrimidines/as-Triazines

The mixture of the heterocyclic base (*N*-1-propargyluracil, *N*-1-propargylthymine, and *N*-1-propargyl-6-azauracil, 1 mmol), K₂CO₃ (0.5 mmol) and propargylbromide (1.1 mmol) in anhydrous DMF (20 mL) was stirred at room temperature during 15 h. After removal of the solvent under reduced pressure and purification on silica gel column chromatography, we obtained the desired pure product.

N-1,*N*-3-dipropargyl-6-azauracil (**11c**). Yield: 85%. ¹H-NMR (DMSO-d₆, δ): 2.98 (t, 1H, CH); 3.44 (t, 1H, CH); 4.48 (d, 2H, CH₂N); 4.67 (d, 2H, CH₂N); 7.58 (s, 1H, H-5). ¹³C-NMR (DMSO-d₆, δ): 29.38; 39.40; 73.50; 75.43; 77.36; 77.64; 134.81; 147.11; 154.90. FAB-MS, *m/z* calcd for C₈H₈N₂O₂ (M+H)⁺ 190.05 found, 190.

3.4. General Procedure for the Synthesis of the Triazole acyclonucleoside Derivatives

The mixture of alkylazide (5 mmol), Et₃N (1 mmol), *N*-propargylbase (1 mmol) and CuI (0.1 mmol) was irradiated in the microwave oven at power level (300 W) for 1 min without solvent. K₂CO₃ (2 mmol) in methanol (10 mL) was added directly to reaction mixture. The mixture was stirred for additional 3 h at room temperature (or in 30 mL of methanol saturated with ammonia at 0 °C during 24 h). When TLC analysis showed no starting material, solvent was removed under reduced pressure, and the residue was purified on silica gel eluting with dichloromethane and methanol.

1-[[*1*-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]uracil (**10a**). Yield: 91%. ¹H-NMR (DMSO-d₆, δ): 1.44–1.29 (m, 2H, CH₂); 1.90–1.75 (m, 2H, CH₂); 3.45–3.37 (m, 2H, OCH₂); 4.35 (t, 2H, CH₂-T, *J* = 7.13); 4.47 (t, 1H, OH, *J* = 4.62); 4.94 (s, 2H, T-CH₂-B); 5.60 (d, 1H, H-5, *J* = 7.85 Hz); 7.75 (d, 1H, H-6, *J* = 7.87 Hz); 8.08 [s, 1H, H-5(triazole)]; 11.31 (s, 1H, NH). ¹³C-NMR (DMSO-d₆, δ): 26.56; 29.24; 42.39; 49.34; 59.98; 101.23; 123.36; 142.23; 145.44; 150.72; 163.65. (MALDI-TOF-MS) *m/z* calcd for C₁₁H₁₅N₅O₃ 265.12, found, 266.87.

1-[[*1*-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]thymine (**10b**). Yield: 92%. ¹H-NMR (DMSO-d₆, δ): 1.44–1.30 (m, 2H, CH₂); 1.76 (s, 3H, CH₃); 1.85 (m, 2H, CH₂); 3.44–3.36 (m, 2H, OCH₂); 4.34 (t, 2H, CH₂-T, *J* = 7.15 Hz); 4.47 (t, 1H, OH, *J* = 5.10 Hz); 4.90 (s, 2H, T-CH₂-B); 7.62 (s, 1H, H-6), 8.07 [s, 1H, H-5(triazole)]; 11.30 (s, 1H, NH). ¹³C-NMR (DMSO-d₆, δ): 11.91; 26.56;

29.25; 42.23; 49.33; 59.98; 108.83; 123.32; 141.11; 142.40; 150.69; 164.24. (MALDI-TOF-MS) m/z calcd for $C_{12}H_{17}N_5O_3$ 279.13, found, 279.07.

1-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]-6-azauracil (10c). Yield: 90%. 1H -NMR (DMSO- d_6 , δ): 1.37 (m, 2H, CH_2); 1.90–1.73 (m, 2H, CH_2); 3.43–3.37 (m, 2H, OCH_2); 4.32 (t, 2H, CH_2 -T, $J = 7.16$); 4.47 (s, 1H, OH); 4.98 (s, 2H, T- CH_2 -B); 7.56 (s, 1H, H-5); 8.02 [s, 1H, H-5(triazole)]; 12.64 (s, 1H, NH). ^{13}C -NMR (DMSO- d_6 , δ): 26.55; 29.25; 34.52; 49.27; 59.99; 123.32; 134.75; 141.48; 148.86; 155.89. (MALDI-TOF-MS) m/z calcd for $C_{10}H_{14}N_6O_3$ 266.11, found, 266.64.

1-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]adenine (10d). Yield: 89%. 1H -NMR (DMSO- d_6 , δ): 1.35 (m, 2H, CH_2); 1.79 (m, 2H, CH_2); 3.39 (m, 2H, OCH_2); 3.47 (s, 1H, OH); 4.33 (t, 2H, T, $J = 7.13$ Hz); 5.44 (s, 2H, T- CH_2 -B); 7.24 (s, 2H, NH_2); 8.10 [s, 1H, H-5(triazole)]; 8.15 and 8.20 (s, 2H, H-2 and H-8). ^{13}C -NMR (DMSO- d_6 , δ): 26.55; 29.21; 38.02; 49.33; 59.95; 118.57; 123.39; 140.61; 142.42; 149.29; 155.96; 152.55. (MALDI-TOF-MS) m/z calcd for $C_{12}H_{16}N_8O$ 288.14, found, 288.11.

1,3-bis-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]uracil (12a). Yield: 90%. 1H -NMR (DMSO- d_6 , δ): 1.44–1.29 [m, 4H, $2 \times (CH_2)$]; 1.90–1.73 [m, 4H, $2 \times (CH_2)$]; 3.40 [m, 4H, $2 \times (OCH_2)$]; 4.32 [m, 4H, $2 \times (CH_2)$]; 4.47 [s, 2H, $2 \times (OH)$]; 5.02 [s, 4H, $2 \times (T-CH_2-B)$]; 5.78 (d, 1H, H-5, $J = 7.89$ Hz); 7.84 (d, 1H, H-6, $J = 7.91$ Hz); 7.92 [s, 1H, H-5(triazole)]; 8.10 [s, 1H, H-5(triazole)]. ^{13}C -NMR (DMSO- d_6 , δ): $2 \times (C)$ 26.56; $2 \times (C)$ 29.24; 35.84; 43.59; 49.22; 49.36; $2 \times (C)$ 59.99; 100.50; 123.15; 123.52; 141.98; 142.48; 144.21; 150.74; 161.99. (MALDI-TOF-MS) m/z calcd for $C_{18}H_{26}N_8O_4$ 418.21, found, 418.46

1,3-bis-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]thymine (12b). Yield: 92%. 1H -NMR (DMSO- d_6 , δ): 1.45–1.30 [m, 4H, $2 \times (CH_2)$]; 1.90–1.75 [m, 7H, $2 \times (CH_2)$ and CH_3]; 3.40 [m, 4H, $2 \times (OCH_2)$]; 4.32 [m, 4H, $2 \times (CH_2-T)$]; 4.49 [s, 2H, $2 \times (OH)$]; 4.98 (s, 2H, T- CH_2 -B); 5.05 (s, 2H, T- CH_2 -B); 5.74 (s, 1H, H-6); 7.91 [s, 1H, H-5(triazole)]; 8.09 [s, 1H, H-5(triazole)]. ^{13}C -NMR (DMSO- d_6 , δ): 12.56; $2 \times (C)$ 26.57; $2 \times (C)$ 29.26; 36.10; 43.43; 49.21; 49.35; $2 \times (C)$ 59.98; 108.09; 123.16; 123.47; 140.05; 142.15; 142.56; 150.58; 162.73. (MALDI-TOF-MS) m/z calcd for $C_{19}H_{28}N_8O_4$ 432.22, found, 432.64.

1,3-bis-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]-6-azauracil (12c). Yield: 91%. 1H -NMR (DMSO- d_6 , δ): 1.36 [m, 4H, $2 \times (CH_2)$]; 1.81 [m, 4H, $2 \times (CH_2)$]; 3.37 [m, 4H, $2 \times (OCH_2)$], 4.32 [m, 4H, $2 \times (CH_2-T)$]; 4.43 (s, 2H, $2 \times (OH)$); 4.80 (s, 2H, T- CH_2 -B); 5.06 (s, 2H, T- CH_2 -B); 7.14 (s, 1H, H-5); 7.91 [s, 1H, H-5(triazole)]; 7.98 [s, 1H, H-5(triazole)]. ^{13}C -NMR (DMSO- d_6 , δ): $2 \times (C)$ 26.5; $2 \times (C)$ 29.27; 35.71; 36.65; $2 \times (C)$ 49.23; $2 \times (C)$ 59.95; 122.71; $2 \times (C)$ 122.94; $2 \times (C)$ 141.89; 145.40; 155.46. (MALDI-TOF-MS) m/z calcd for $C_{17}H_{25}N_9O_4$ 419.20, found, 419.17.

4. Conclusions

A series of triazole carboacyclonucleosides with various nucleobase moieties appended on the triazole were synthesized efficiently using a convenient one-step click azide-alkyne cycloaddition reaction under solvent-free microwave irradiation. All compounds synthesized were evaluated for their

antibacterial and antiviral activities but none exhibited specific activity so far. Further applications of the click azide-alkyne cycloaddition process are currently under investigation and will be reported in due course.

Acknowledgements

We gratefully acknowledge the experimental help in testing the compounds by Phil Dudfield VP, Alliances and Informatics Galapagos NV 102, avenue Gaston Roussel 93230 Romainville.

References and Notes

1. Schinazi, R.F.; Mead, J.R.; Feorino, P.M. Insights into HIV chemotherapy. *AIDS Res. Hum. Retrovirus.* **1992**, *8*, 963-990.
2. Clercq, E.D. HIV inhibitors targeted at the reverse transcriptase *AIDS Res. Hum. Retrovirus.* **1992**, *8*, 119-134.
3. EASL International Consensus Conference on Hepatitis C. Consensus Statement. *J. Hepatol.* **1999**, *31*, 3-8.
4. Wengel, J.; Schinazi, R.F.; Caruthers, M.H. Stereoselective synthesis, chemistry and antiviral evaluation of 1-(2,3-dideoxy-3-C-hydroxymethyl-beta-D-threo-pentofuranosyl)thymine derivatives. *Bioorg. Med. Chem.* **1995**, *3*, 1223-1229.
5. Sekiyama, T.; Hatsuya, S.; Tanaka, Y.; Uduyama, M.; Ono, N.; Iwayama, S.; Oikawa, M.; Suzuki, K.; Okunishi, M.; Tsuji, T. Synthesis and antiviral activity of novel acyclic nucleosides: Discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses. *J. Med. Chem.* **1998**, *41*, 1248-1298.
6. Nasr, M.; Litterst, C.; McGowan, J. Computer-assisted structure-activity correlations of dideoxynucleoside analogs as potential anti-HIV drugs. *Antiviral Res.* **1990**, *14*, 125-148.
7. Prasad, A.K.; Trikha, S.; Parmar, V.S. Nucleoside synthesis mediated by glycosyl transferring enzymes. *Bioorg. Chem.* **1999**, *27*, 135-154.
8. Chu, C.K.; Cutler, S.J.; Chu, C.K.; Cutler, S.J. Chemistry and antiviral activities of acyclonucleosides. *J. Heterocycl. Chem.* **1986**, *23*, 289-319.
9. Parkanyi, C.; Yuan, H.L. Synthesis of acyclic nucleoside analogs of 6-substituted 2-aminopurines and 2-amino-8-azapurines. *J. Heterocycl. Chem.* **1990**, *27*, 1409-1413.
10. Pan, B.-C.; Chem, Z.-H.; Piras, G.; Dutschman, G.E.; Rowe, E.C.; Cheng, Y.-C.; Chu, S.-H. Synthesis and anti-HIV-1 activities of 6-arylthio and 6-arylselenoacyclonucleosides. *J. Heterocycl. Chem.* **1994**, *31*, 177-185.
11. Chen, W.; Flavin, M.T.; Filler, R.; Xu, Z.-Q. Synthesis and antiviral activities of fluorinated acyclic nucleoside phosphonates. *J. Chem. Soc. Perkin Trans. I* **1998**, 3979-3988.
12. Hirota, K.; Monguchi, Y.; Sajiki, H.; Sako, M.; Kitada, Y. Novel synthesis of purine acyclonucleosides possessing a chiral 9-hydroxyalkyl group by sugar modification of 9-D-riboityl purines. *J. Chem. Soc. Perkin Trans. I* **1998**, 941-946.
13. Chu, C.K.; Baker, D.C. *Nucleosides and Nucleotides as Antitumor and Antiviral Agents*; Plenum Press: New York, NY, USA, 1993; pp. 101-113.

14. El Ashry, E.S.H.; El Kilany, Y. Acyclonucleosides: Part 3. tri-, tetra-, and pentaseco-nucleosides. *Adv. Heterocycl. Chem.* **1998**, *69*, 129-215.
15. El Ashry, E.S.H.; El Kilany, Y. Acyclonucleosides: Part 2. Diseco-nucleosides. *Adv. Heterocycl. Chem.* **1997**, *68*, 1-88.
16. El Ashry, E.S.H.; El Kilany, Y. Acyclonucleosides: Part 1. Seco-nucleosides. *Adv. Heterocycl. Chem.* **1996**, *67*, 391-438.
17. Rashed, N.; Abdel Hamid, H.; Ramadan, E.S.; El Ashry, E.S.H. Acyclo C-nucleoside analogues. Regioselective anellation of a triazole ring to 5-methyl-1,2,4-triazino[5,6-b]indole and formation of certain 3-poly hydroxyalkyl derivatives. *Nucleos. Nucleot.* **1998**, *17*, 1373-1384.
18. El Ashry, E.S.H.; El Kholy, I.E.; El Kilany, Y. Dehydrative ring-closure of 3-substituted 2-quinoxalinones to give fused and nonfused pyrazoloquinoxalines. *Carbohydr. Res* **1978**, *60*, 303-314.
19. Sidwell, R.W.; Huffman, J.H.; Khare, G.P.; Allen, L.B.; Witkowski, J.T.; Robins, R.K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide. *Science* **1972**, *177*, 705-706.
20. Manfredini, S.; Vicentini, C.B.; Manfrini, M.; Bianchi, N.; Rutigliano, A.; Mistiachi, C.; Gambari, R. Pyrazolo-triazoles as light activable dna cleaving agents. *Bioorg. Med. Chem.* **2000**, *8*, 2343-2346.
21. Gothelf, K.V.; Jørgensen, K.A. Asymmetric 1,3-dipolar cycloaddition reactions. *Chem. Rev.* **1998**, *98*, 863-910.
22. Lazrek, H.B.; Taourirte, M.; Oulih, T.; Barascut, J.L.; Imbach, J.L.; Pannecouque, C.; Witrouw, M.; De Clercq, E. Synthesis and anti-Hiv activity of new modified 1,2,3-triazole acyclonucleosides. *Nucleos. Nucleot.* **2001**, *20*, 1949-1960.
23. Rostovtsev Green, V.V.L.G.; Fokin, V.V.; Sharpless, K.B. Stepwise huisgen cycloaddition process: Copper(I)-catalyzed regioselective ligation of azides and terminal alkynes. *Angew. Chem. Int. Ed.* **2002**, *41*, 2596-2599.
24. Tornfe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-Triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. *J. Org. Chem.* **2002**, *67*, 3057-3064.
25. Wang, Q.; Chan, T.R.; Hilgraf, R.; Fokin, V.V.; Sharpless, K.B.; Finn, M.G. Bioconjugation by copper(I)-catalyzed azide-alkyne [3+2] cycloaddition. *J. Am. Chem. Soc.* **2003**, *125*, 3192-3193.
26. Lober, S.; Rodriguez-Loaiza, P.; Gmeiner, P. Click linker: Efficient and high-yielding synthesis of a new family of SPOS resins by 1,3-dipolar cycloaddition. *Org. Lett.* **2003**, *5*, 1753-1755.
27. Pérez-Balderas, F.; Ortega-Munoz, M.; Morales-Sanfrutos, J.; Hernández-Mateo, F.; CalvoFlores, F.G.; Calvo-Asín, J.A.; Isac-García, J.; Santoyo González, F. Multivalent neoglycoconjugates by regiospecific cycloaddition of alkynes and azides using organic-soluble copper catalysts. *Org. Lett.* **2003**, *5*, 1951-1954.
28. Krasinski, A.; Fokin, V.V.; Sharpless, K.B. Direct synthesis of 1,5-disubstituted-4-magnesio-1,2,3-triazoles, revisited. *Org. Lett.* **2004**, *6*, 1237-1240.
29. Kamijo, S.; Jin, T.; Huo, Z.; Yamamoto, Y. Synthesis of triazoles from nonactivated terminal alkynes via the three-component coupling reaction using a Pd(0)-Cu(I) bimetallic catalyst. *J. Am. Chem. Soc.* **2003**, *125*, 7786-7787.

30. Kamijo, S.; Jin, T.; Huo, Z.; Yamamoto, Y. A one-pot procedure for the regiocontrolled synthesis of allyltriazoles via the Pd-Cu bimetallic catalyzed three-component coupling reaction of nonactivated terminal alkynes, allyl carbonate, and trimethylsilyl azide. *J. Org. Chem.* **2004**, *69*, 2386-2393.
31. Yan, Z.Y.; Zhao, Y.B.; Fan, M.J.; Liu, W.M.; M.Liang, Y. General synthesis of (1-substituted-1*H*-1,2,3-triazol-4-ylmethyl)-dialkylamines via a copper(I)-catalyzed three-component reaction in water. *Tetrahedron* **2005**, *61*, 9331-9337.
32. Chittepu, P.; Sirivolu, V.R.; Seela, F. Nucleosides and oligonucleotides containing 1,2,3-triazole residues with nucleobase tethers: Synthesis via the azide-alkyne 'click' reaction. *Bioorg. Med. Chem.* **2008**, *16*, 8427-8439.
33. El Akri, K.; Bougrin, K.; Balzarini, B.J.; Faraj, A.; Benhida, R. Efficient synthesis and *in vitro* cytostatic activity of 4-substituted triazolyl-nucleosides. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6656-6659.
34. Krim, J.; Sillahi, B.; Taourirte, M.; Rakib, E.M.; Engels, J.W. Microwave-assisted click chemistry: Synthesis of mono and bis-1,2,3-triazole acyclonucleoside analogues of ACV via copper(I)-catalyzed cycloaddition. *ARKIVOC* **2009**, *xiii*, 142-152.
35. Lucas, R.; Neto, V.; Bouazza, A.H.; Zerrouki, R.; Granet, R.; Krausz, P.; Yves Champavier, Y. Microwave-assisted synthesis of a triazole-linked 3'-5' dithymidine using click chemistry. *Tetrahedron Lett.* **2008**, *49*, 1004-1007.
36. Keller, P.M.; Fyfe, A.; Beauchamp, L.; Lubbers, C.M.; Furman, P.A.; Schaeffer, H.J.; Elion, G.B. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. *Biochem. Pharmacol.* **1981**, *30*, 3071-3077.
37. CLSI-Clinical and Laboratory Standards Institute. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that grow Aerobically, Approved Standard M7-A7*, 7th ed.; CLSI: Wayne, PA, USA, 2006.

Sample Availability: Not available.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).